Hypoxia-activated prodrugs in cancer therapy: progress to the clinic

Hypoxic regulation of mRNA expression

(2011) Lawrence Gardner et al.   CELL CYCLE

Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters

(2009) Frederik B. Pruijn et al.   AUSTRALIAN JOURNAL OF CHEMISTRY

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

(2009) Michael B. Jameson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone

(2009) O. Tredan et al.   CANCER RESEARCH

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH

Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222

(2009) Quynh-Thu X. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Spin Trapping of Radicals Other Than the•OH Radical upon Reduction of the Anticancer Agent Tirapazamine by Cytochrome P450Reductase

(2009) Sujata S. Shinde et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N)

(2009) M. Mehibel et al.   MOLECULAR CANCER THERAPEUTICS

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

(2009) Y. Gu et al.   MOLECULAR CANCER THERAPEUTICS

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

(2009) Pasi A. Jänne et al.   NATURE REVIEWS DRUG DISCOVERY

Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates

(2009) Arun Jain et al.   UROLOGY

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer

(2009) Kees Hendricksen et al.   WORLD JOURNAL OF UROLOGY

Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells

(2008) J. W. Evans et al.   CANCER RESEARCH

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

(2008) M. R. Albertella et al.   CLINICAL CANCER RESEARCH

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

(2008) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

Tirapazamine: a novel agent targeting hypoxic tumor cells

(2008) Srini B Reddy et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Reductive Heme-Dependent Activation of theN-Oxide Prodrug AQ4N by Nitric Oxide Synthase

(2008) Clinton R. Nishida et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins

(2008) Michael P. Hay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

(2008) Jian-Xin Duan et al.   JOURNAL OF MEDICINAL CHEMISTRY